AstraZeneca PLC AZN.ST
Composite 52/100; the shares have moved about 29% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 17/100 — a strong mark against it.
Quality ranks 75/100 — a strong point in its favour. Growth ranks 74/100 — a moderate point in its favour. Balance-sheet strength ranks 60/100 — a slight point in its favour.
Valuation ranks 17/100 — a strong mark against it. Momentum ranks 30/100 — a moderate mark against it.
What the company does AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing prescription medicines across oncology, cardiovascular, respiratory & immunology, and rare diseases.
Key financials Strong profitability metrics: ROE 23.5%, ROA 8.5%, ROCE 17.9%. Gross margin 81.5%, operating margin 27.9%, net margin 17.2%. Revenue growth 12.5%, EPS growth 5.3%. Debt/Equity 0.64, net debt/EBITDA 1.38, interest coverage 8.33.
Stock health Sideravia overall score 54.6 (Strong quality, richly valued). Quality pillar 76.8, Valuation pillar 26.1. Piotroski F-Score 8/9, Altman Z 24.45. Dividend yield 0.0%, payout 47.4%.
Price vs fair value The stock trades at a PREMIUM of 8.50% versus our fair-value estimate and a discount of 12.58% versus the analyst 12-month target. - Sector-wide healthcare decline pressured AZN late afternoon (MT Newswires) - Mixed Ultomiris data and Sonepc Ve Win scrutiny weighed on sentiment (Simply Wall St.) - Biogen’s resiliency and GSK’s oncology push highlighted competitive dynamics (BioPharma Dive) - Simply Wall St questioned whether AZN’s value is underappreciated (Simply Wall St.)
Looking forward Forward P/E 16.39, PEG 0.28, EV/EBITDA 14.29. Analysts see potential upside to 1906.51, supported by pipeline strength and margin resilience.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.